Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.

Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, Fonzetti P, Hegel M, Arndt S.

JAMA. 2008 May 28;299(20):2391-400. doi: 10.1001/jama.299.20.2391. Erratum in: JAMA. 2009 Mar 11;301(10):1024.

2.

Escitalopram and enhancement of cognitive recovery following stroke.

Jorge RE, Acion L, Moser D, Adams HP Jr, Robinson RG.

Arch Gen Psychiatry. 2010 Feb;67(2):187-96. doi: 10.1001/archgenpsychiatry.2009.185.

3.

Escitalopram, problem-solving therapy, and poststroke depression.

Rasmussen A, Hanash JA, Bech P.

JAMA. 2008 Oct 15;300(15):1758; author reply 1758-9. doi: 10.1001/jama.300.15.1758-a. No abstract available.

PMID:
18854531
4.

Escitalopram, problem-solving therapy, and poststroke depression.

Schulte-Herbrüggen O, Röpke S.

JAMA. 2008 Oct 15;300(15):1757; author reply 1758-9. doi: 10.1001/jama.300.15.1757-a. No abstract available.

PMID:
18854530
5.

Escitalopram, problem-solving therapy, and poststroke depression.

Dettling M, Opgen-Rhein C, Anghelescu I.

JAMA. 2008 Oct 15;300(15):1757; author reply 1758-9. doi: 10.1001/jama.300.15.1757-b. No abstract available.

PMID:
18854529
6.

Escitalopram, problem-solving therapy, and poststroke depression.

Lacasse J, Leo J.

JAMA. 2008 Oct 15;300(15):1757-8; author reply 1758-9. doi: 10.1001/jama.300.15.1757-c. No abstract available.

PMID:
18854528
7.

Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: randomized, double-blind, placebo-controlled clinical trial.

Lydiatt WM, Bessette D, Schmid KK, Sayles H, Burke WJ.

JAMA Otolaryngol Head Neck Surg. 2013 Jul;139(7):678-86. doi: 10.1001/jamaoto.2013.3371.

PMID:
23788218
8.

Prevention of poststroke apathy using escitalopram or problem-solving therapy.

Mikami K, Jorge RE, Moser DJ, Arndt S, Jang M, Solodkin A, Small SL, Fonzetti P, Hegel MT, Robinson RG.

Am J Geriatr Psychiatry. 2013 Sep;21(9):855-62. doi: 10.1016/j.jagp.2012.07.003. Epub 2013 Feb 6.

PMID:
23930743
9.

Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.

Angermann CE, Gelbrich G, Störk S, Gunold H, Edelmann F, Wachter R, Schunkert H, Graf T, Kindermann I, Haass M, Blankenberg S, Pankuweit S, Prettin C, Gottwik M, Böhm M, Faller H, Deckert J, Ertl G; MOOD-HF Study Investigators and Committee Members.

JAMA. 2016 Jun 28;315(24):2683-93. doi: 10.1001/jama.2016.7635.

PMID:
27367876
10.

Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.

Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C.

J Clin Psychiatry. 2006 Nov;67(11):1767-75.

PMID:
17196058
11.

Incomplete financial disclosure in a study of escitalopram and problem-solving therapy for prevention of poststroke depression.

Robinson RG, Arndt S.

JAMA. 2009 Mar 11;301(10):1023-4. doi: 10.1001/jama.2009.256. No abstract available.

PMID:
19278945
12.

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM.

Curr Med Res Opin. 2007 Feb;23(2):401-16.

PMID:
17288694
13.

Increased frequency of first-episode poststroke depression after discontinuation of escitalopram.

Mikami K, Jorge RE, Moser DJ, Arndt S, Jang M, Solodkin A, Small SL, Fonzetti P, Hegel MT, Robinson RG.

Stroke. 2011 Nov;42(11):3281-3. doi: 10.1161/STROKEAHA.111.626507. Epub 2011 Aug 25.

14.

Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.

Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T.

Ann Intern Med. 2012 Jul 17;157(2):94-103. doi: 10.7326/0003-4819-157-2-201207170-00006.

PMID:
22801672
15.

Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial.

Kim JM, Bae KY, Stewart R, Jung BO, Kang HJ, Kim SW, Shin IS, Hong YJ, Kim JH, Shin HY, Kang G, Ahn Y, Kim JK, Jeong MH, Yoon JS.

J Clin Psychiatry. 2015 Jan;76(1):62-8. doi: 10.4088/JCP.14m09281.

PMID:
25375836
16.

Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.

Jiang W, Velazquez EJ, Kuchibhatla M, Samad Z, Boyle SH, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, O'Connor C.

JAMA. 2013 May 22;309(20):2139-49. doi: 10.1001/jama.2013.5566.

17.

Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.

Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R.

Arch Gen Psychiatry. 2008 May;65(5):551-62. doi: 10.1001/archpsyc.65.5.551.

PMID:
18458207
18.

Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.

Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H, Carpenter JS, Anderson GL, Larson JC, Ensrud KE, Reed SD, Newton KM, Sherman S, Sammel MD, LaCroix AZ.

JAMA. 2011 Jan 19;305(3):267-74. doi: 10.1001/jama.2010.2016.

19.

Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial.

Lenze EJ, Rollman BL, Shear MK, Dew MA, Pollock BG, Ciliberti C, Costantino M, Snyder S, Shi P, Spitznagel E, Andreescu C, Butters MA, Reynolds CF 3rd.

JAMA. 2009 Jan 21;301(3):295-303. doi: 10.1001/jama.2008.977.

20.

Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study.

Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, Curdue K, Petracca G, Starkstein SE.

Am J Psychiatry. 2000 Mar;157(3):351-9.

PMID:
10698809

Supplemental Content

Support Center